Phase I Open-label, Single Dose Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics (PK) of Evobrutinib (M2951)
Latest Information Update: 14 Jul 2021
Price :
$35 *
At a glance
- Drugs Evobrutinib (Primary)
- Indications Autoimmune disorders; Encephalomyelitis; Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus
- Focus Pharmacokinetics
- Sponsors Merck KGaA
- 09 Jul 2021 Status changed from active, no longer recruiting to completed.
- 17 Jun 2021 Status changed from recruiting to active, no longer recruiting.
- 07 Oct 2020 Status changed from not yet recruiting to recruiting.